KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $22.9 million.

  • Arbutus Biopharma's Cash from Investing Activities rose 16.41% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year decrease of 4.44%. This contributed to the annual value of $22.9 million for FY2024, which is 54.80% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Investing Activities of $22.9 million as of FY2024, which was down 54.80% from $50.8 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Cash from Investing Activities high stood at $50.8 million for FY2023, and its period low was -$74.9 million during FY2022.
  • In the last 3 years, Arbutus Biopharma's Cash from Investing Activities had a median value of $22.9 million in 2024 and averaged -$407,000.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 491.12% in 2022, then surged by 167.75% in 2023.
  • Yearly analysis of 5 years shows Arbutus Biopharma's Cash from Investing Activities stood at -$14.9 million in 2020, then grew by 14.96% to -$12.7 million in 2021, then plummeted by 491.12% to -$74.9 million in 2022, then spiked by 167.75% to $50.8 million in 2023, then crashed by 54.80% to $22.9 million in 2024.